Star Health and Allied Insurance Company Limited – Investor Presentation Summary

Key Operational Highlights

  • Gross Written Premium (GWP) grew 13% YoY to ₹4,917 crore in Q1 FY27 from ₹4,336 crore in Q1 FY26.
  • Retail Fresh GWP (Retail Health) grew 12% YoY to ₹4,471 crore in Q1 FY27 from ₹3,990 crore in Q1 FY26.
  • The Combined Insurance Service Ratio (CISR) improved to 97.0% in Q1 FY27 from 98.7% in Q1 FY26.
  • Underwriting Result improved significantly to ₹111 crore in Q1 FY27 from ₹16 crore in Q1 FY26, a 600% increase.
  • Key drivers include disciplined portfolio management, proprietary distribution network strength, and technology integration across the value chain.

Financial Highlights

  • Revenue: Not explicitly stated as a line item; primary revenue metric is Insurance Revenue/GWP.
  • Profit After Tax (PAT): ₹550 crore in Q1 FY27, up 25% YoY from ₹438 crore in Q1 FY26.
  • Investment Income: ₹644 crore in Q1 FY27, up 10% YoY from ₹586 crore in Q1 FY26.
  • Investment Yield (Annualised): 12.2% in Q1 FY27 compared to 13.1% in Q1 FY26.
  • Return On Equity (ROE; Annualised): 22.3% in Q1 FY27 compared to 19.7% in Q1 FY26.
  • Normalised PAT (at normalised investment portfolio yield of 8%): ₹386 crore in Q1 FY27, up from ₹267 crore in Q1 FY26.
  • Normalised ROE (Annualised): 15.6% in Q1 FY27 compared to 12.2% in Q1 FY26.
  • YoY comparison: Key metrics show improvement in profitability and operational efficiency.
  • Drivers of financial performance: Higher underwriting profit (₹111 crore vs. ₹16 crore), growth in investment income, and improved combined ratio.
  • Key Risks: Not explicitly disclosed in the provided data.

Segment-wise Performance

  • Performance is primarily reported for the consolidated entity. A segmental breakdown is not provided in the data.

Geographical Revenue Split

  • A geographical revenue split is not provided in the data.

Balance Sheet Snapshot

  • Shareholder Net worth: ₹10,144 crore as of June 30, 2026, compared to ₹9,110 crore as of June 30, 2025.
  • Financial Health Insights: Not explicitly detailed beyond the growth in net worth.

Capex & Cash Flow Health

  • Capital Expenditure: Not specified.
  • Free Cash Flow: Not specified.
  • Operating Cash Flow: Not specified.
  • Net Debt Movement: Not specified.
  • Investment Rationale: Focus on technology and distribution capabilities is implied.

Strategic & R&D Initiatives

  • Investments in Innovation: Twenty years of proprietary data on a unified layer with AI/ML at scale. Distribution App (ATOM Pro) for hyper-personalized quotes and agent efficiency. Customer app for engagement. AI/ML in claims processing.
  • Expected impact on growth: Technology aims to enhance distribution efficiencies, customer engagement, and claims processing outcomes.
  • Strategic Rationale: Building a compounding distribution moat through the largest agency-led health network and growing Digital D2C channel. Conscious risk-selection for portfolio quality.

Industry Trends & Business Environment

  • Macro/Industry Trends: Not explicitly detailed in the provided slides.
  • Impact on Company: Not specified.

Management Commentary & Growth Outlook

  • Strategic Outlook: The presentation emphasizes building a "compounding distribution moat" and "sustainable profitable growth enabled by disciplined portfolio management."
  • FY Guidance: Not provided in the data.
  • Market Share Targets: Not provided in the data.
  • Risks and Opportunities: Not highlighted in the provided excerpts.

ESG Updates

  • Environment: Renewable energy consumption reached 6,817.65 GJ. Recycled 13.90 tonnes of e-waste and 11.08 tonnes of battery waste. Saved 102.7 million paper pages through digital initiatives. Climate risk framework strengthened.
  • Social: 100% employee coverage under awareness and training. Woman workforce representation increased from 29% to 32%. Reduced employee attrition. Continued investment in capability building and customer experience.
  • Governance: BRSR Reasonable Assurance for Core parameters undertaken. ESG governance strengthened through enhanced oversight.

CSR Initiative

  • Arogya Seva Kendra operational in 9 states, targeting outreach to over 1 million lives in underserved districts. 32 clinics operational with 56,794 visits and 1,921 medical tests done. 52,005 pneumococcal vaccinations administered.